Starsource Multitrade Limited (formerly Chemo Pharma Laboratories Limited) reported its unaudited financial results for the quarter ended June 30, 2026. The company posted a consolidated net profit of ₹6.1 crore against income from operations of ₹86.4 crore. On a standalone basis, net profit was ₹1.3 crore on revenue of ₹18.6 crore.

The Board of Directors approved the results in a meeting held on August 14, 2026. The financial statements were prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013.

Financial Highlights

What the Numbers Show

The divergence between standalone and consolidated figures indicates significant contribution from subsidiaries or associates. While standalone operations generated ₹18.6 crore in revenue, the consolidated top line was ₹86.4 crore, suggesting that the majority of the company's operational activity is captured through its group entities. The consolidated net profit margin stood at approximately 7%, compared to a 7% margin on a standalone basis, indicating consistent profitability across both structures.

Regulatory Disclosures

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published the unaudited financial results in Business Standard and Mumbai Lakshdeep on August 15, 2026. The results were reviewed by the Audit Committee before board approval.

The full format of the financial results is available on the company's website and the stock exchange portals. Figures have been regrouped and rearranged wherever necessary to align with current period classification.

Starsource Multitrade Limited reported a net loss of ₹118.55 crore for the financial year ended March 31, 2026, a significant reversal from the net profit of ₹3.42 crore recorded in the previous year. The company's board approved the audited standalone financial results for the fourth quarter and fiscal year 2026 during a meeting held on May 29, 2026. Total income for the year stood at ₹5.49 crore, down from ₹6.20 crore in FY25, while total expenditure surged to ₹124.04 crore from ₹1.22 crore in the prior year.

Financial Performance

The deterioration in financial performance was primarily driven by a sharp increase in other expenses, which rose to ₹119.38 crore from ₹0.95 crore in the previous year. For the quarter ended March 31, 2026, the company reported a net loss of ₹0.71 crore on a total income of ₹0.01 crore. Basic and diluted earnings per share (EPS) for the year were negative at ₹79.03, compared to a positive EPS of ₹2.28 in FY25.

Auditor's Observations

The statutory auditor, M/s. S S R V & Associates, issued an unmodified opinion on the financial results. However, the report highlighted material discrepancies, noting that only agricultural sales were recorded in the books of accounts, whereas a higher turnover was reported in GST returns. The auditor stated that no reconciliation or explanation for this variance was provided by the management. Additionally, balance confirmations from various parties were not made available for verification, and a loss on fair value change in investments booked under indirect expenses was deemed unsupported by adequate explanations.

Key Financial Metrics

The board also confirmed that the financial statements do not contain any false or misleading statements. The trading window for dealing in the company's shares by designated persons, which had been closed since April 01, 2026, will re-open 48 hours after the announcement of these results.